Comprehensive Stock Comparison
Compare Insight Molecular Diagnostics Inc. (IMDX) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  IMDX | Beta 0.43 vs PHGE's 0.93 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | IMDX | +51.1% vs PHGE's -48.8% |
| Efficiency (ROA) | IMDX | -138.3% ROA vs PHGE's -142.8% |
Who Each Stock Is For
Income & stability
IMDXDividend streak 1 yrs, beta 0.43
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
IMDX-94.0% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
IMDXLower volatility, beta 0.43, current ratio 1.62x
Defensive / Recession hedge
IMDXBeta 0.43, current ratio 1.62x
Business Model
What each company does and how it makes money
Insight Molecular Diagnostics is a molecular diagnostics company that develops and commercializes proprietary laboratory-developed tests for cancer detection. It generates revenue primarily from its DetermaRx test for early-stage lung cancer and DetermaIO gene expression assay — along with biomarker discovery services for pharmaceutical companies. The company's competitive advantage lies in its proprietary gene expression technology and collaborations with major sequencing platform providers like Life Technologies.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
IMDX 4PHGE 1IMDX1/1 metricsPHGE1/1 metricsIMDX4/7 metricsIMDX5/6 metricsIMDX2/2 metricsIMDX leads in 4 of 6 categories (Financial Metrics, Profitability & Efficiency). PHGE leads in 1 (Valuation Metrics).
Financial Metrics (TTM)
IMDX and PHGE operate at a comparable scale, with $4M and $0 in trailing revenue.
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $4M | $0 |
| EBITDAEarnings before interest/tax | -$59M | -$6M |
| Net IncomeAfter-tax profit | -$61M | -$37M |
| Free Cash FlowCash after capex | -$24M | -$28M |
| Gross MarginGross profit ÷ Revenue | +54.7% | — |
| Operating MarginEBIT ÷ Revenue | -13.9% | — |
| Net MarginNet income ÷ Revenue | -13.8% | — |
| FCF MarginFCF ÷ Revenue | -5.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +126.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +65.4% | -6.5% |
Valuation Metrics
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $95M | $82.8B |
| Enterprise ValueMkt cap + debt − cash | $90M | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.17x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 50.75x | — |
| Price / BookPrice ÷ Book value/share | — | 3427.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
PHGE delivers a -3.6% return on equity — every $100 of shareholder capital generates $-4 in annual profit, vs $-15 for IMDX. On the Piotroski fundamental quality scale (0–9), IMDX scores 4/9 vs PHGE's 3/9, reflecting mixed financial health.
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -14.8% | -3.6% |
| ROA (TTM)Return on assets | -138.3% | -142.8% |
| ROICReturn on invested capital | — | -3.1% |
| ROCEReturn on capital employed | -127.8% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.40x |
| Net DebtTotal debt minus cash | -$5M | -$8M |
| Cash & Equiv.Liquid assets | $9M | $18M |
| Total DebtShort + long-term debt | $4M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -536.86x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in IMDX five years ago would be worth $735 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, IMDX leads with a +51.1% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors IMDX at -10.3% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -23.6% | +194.4% |
| 1-Year ReturnPast 12 months | +51.1% | -48.8% |
| 3-Year ReturnCumulative with dividends | -27.8% | -93.2% |
| 5-Year ReturnCumulative with dividends | -92.6% | -99.5% |
| 10-Year ReturnCumulative with dividends | -94.0% | -99.7% |
| CAGR (3Y)Annualised 3-year return | -10.3% | -59.1% |
Risk & Volatility
IMDX is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMDX currently trades 64.3% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.43x | 0.93x |
| 52-Week HighHighest price in past year | $8.51 | $14.71 |
| 52-Week LowLowest price in past year | $2.33 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +64.3% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 43.2 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 60K | 1.3M |
Analyst Outlook
| Metric | IMDXInsight Molecular… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $10.50 | — |
| # AnalystsCovering analysts | 11 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Insight Molecular D… (IMDX) | 100 | 10.88 | -89.1% |
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
Insight Molecular D… (IMDX) returned -93% over 5 years vs BiomX Inc. (PHGE)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Insight Molecular D… (IMDX) | $0.00 | $2M | — |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Insight Molecular Diagnostics Inc.'s revenue grew from $0M (2015) to $2M (2024) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Insight Molecular D… (IMDX) | -8.32 | -4.66 | +44.0% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Insight Molecular Diagnostics Inc.'s EPS grew from $-8.32 (2015) to $-4.66 (2024).
Chart 4Free Cash Flow — 5 Years
Insight Molecular Diagnostics Inc. generated $-21M FCF in 2024 (+44% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
IMDX vs PHGE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is IMDX or PHGE a better buy right now?
Analysts rate Insight Molecular Diagnostics Inc. (IMDX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMDX or PHGE?
Over the past 5 years, Insight Molecular Diagnostics Inc. (IMDX) delivered a total return of -92.6%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in IMDX five years ago would be worth approximately $735 today (assuming dividends reinvested). Over 10 years, the gap is even starker: IMDX returned -94.0% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMDX or PHGE?
By beta (market sensitivity over 5 years), Insight Molecular Diagnostics Inc. (IMDX) is the lower-risk stock at 0.43β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 113% more volatile than IMDX relative to the S&P 500.
04Which has better profit margins — IMDX or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -32.3% for Insight Molecular Diagnostics Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -32.5% for IMDX. At the gross margin level — before operating expenses — IMDX leads at 39.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — IMDX or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is IMDX or PHGE better for a retirement portfolio?
For long-horizon retirement investors, Insight Molecular Diagnostics Inc. (IMDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43)). Both have compounded well over 10 years (IMDX: -94.0%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between IMDX and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.